Contraceptive patch

"Evra patch" redirects here. For the brand of patch containing estradiol only, see Evorel patch.
Contraceptive patch
Ortho Evra brand of contraceptive patch
Background
TypeHormonal (combined estrogen + progestin)
First use2002
Failure rates (first year)
Perfect use0.3%[1]
Typical use9%[1]
Usage
User remindersWeekly application for 3 weeks
Clinic review3-6 monthly
Advantages and disadvantages
STI protectionNo
WeightNo proven effect
Period advantagesRegulated, may be lighter and less painful
BenefitsCompared to oral pills, may be less affected by antibiotics
RisksDVTs rates similar to oral combined pills
norelgestromin / ethinyl estradiol
Combination of
NorelgestrominProgestogen
EthinylestradiolEstrogen
Clinical data
Trade namesOrtho Evra, Xulane, Evra
AHFS/Drugs.comProfessional Drug Facts
MedlinePlusa602006
License data
Pregnancy
category
  • Contraindicated
Routes of
administration		Transdermal (patch)
ATC code
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
  • None
UNII
KEGG
Chemical and physical data
FormulaC41H53NO4
Molar mass623.878 g·mol−1
3D model (JSmol)
  • CCC12CCC3C(C1CCC2(C#C)O)CCC4=CC(=NO)CCC34.CC12CCC3C(C1CCC2(C#C)O)CCC4=C3C=CC(=C4)O
  • InChI=1S/C21H29NO2.C20H24O2/c1-3-20-11-9-17-16-8-6-15(22-24)13-14(16)5-7-18(17)19(20)10-12-21(20,23)4-2;1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h2,13,16-19,23-24H,3,5-12H2,1H3;1,5,7,12,16-18,21-22H,4,6,8-11H2,2H3/b22-15-;/t16-,17+,18+,19-,20-,21-;16-,17-,18+,19+,20+/m01/s1
  • Key:KBFRRZPPJPKFHQ-WKXKRCMPSA-N
levonorgestrel / ethinyl estradiol
Combination of
LevonorgestrelProgestogen
EthinylestradiolEstrogen
Clinical data
Trade namesTwirla
License data
Pregnancy
category
  • Contraindicated
Routes of
administration		Transdermal (patch)
ATC code
Legal status
Legal status
Identifiers
ChemSpider
  • None

A contraceptive patch, also known as "the patch", is a transdermal patch applied to the skin that releases synthetic oestrogen and progestogen hormones to prevent pregnancy. They have been shown to be as effective as the combined oral contraceptive pill with perfect use, and the patch may be more effective in typical use.[3][4]

Xulane[5] and Twirla[6] are approved for use in the United States. Evra is approved for use in Canada and marketed by Janssen Inc.,[7] and it is approved for use in the United Kingdom[8] and in Europe[9] and marketed by Janssen-Cilag.[8][9] The patches are packaged in boxes of three and are only available by prescription.[5]

  1. ^ a b Trussell J (2011). "Contraceptive efficacy". In Hatcher RA, Trussell J, Nelson AL, Cates Jr W, Kowal D, Policar MS (eds.). Contraceptive technology (20th revised ed.). New York: Ardent Media. pp. 779–863. ISBN 978-1-59708-004-0. ISSN 0091-9721. OCLC 781956734. Table 26–1 = Table 3–2 Percentage of women experiencing an unintended pregnancy during the first year of typical use and the first year of perfect use of contraception, and the percentage continuing use at the end of the first year. United States. Archived 2017-02-15 at the Wayback Machine
  2. ^ "Evra transdermal patch - Summary of Product Characteristics (SmPC)". (emc). 26 June 2020. Archived from the original on 24 October 2020. Retrieved 4 July 2020.
  3. ^ Trussell J (2007). "Contraceptive Efficacy". In Hatcher RA, et al. (eds.). Contraceptive Technology (19th rev. ed.). New York: Ardent Media. ISBN 978-0-9664902-0-6.
  4. ^ Nanda K, Burke A (2011). "Contraceptive patch and vaginal contraceptive ring.". In Hatcher RA, Nelson AL, Trussell J, Cwiak C, Cason P, Policar MS, Edelman A, Aiken AR, Marrazzo J, Kowal D (eds.). Contraceptive Technology (twentieth ed.). Atlanta, Georgia: Ardent Media, Inc. p. 272. ISBN 978-1-59708-004-0.
  5. ^ a b "Xulane- norelgestromin and ethinyl estradiol patch". DailyMed. 19 April 2017. Retrieved 17 February 2020.
  6. ^ "FDA Approves Agile Therapeutics, Inc.'s Twirla (levonorgestrel and ethinyl estradiol) Transdermal System – A New Weekly Contraceptive Patch Delivering a 30 mcg Daily Dose of Estrogen and 120 mcg Daily Dose of Progestin". Agile Therapeutics. 14 February 2020. Retrieved 17 February 2020.
  7. ^ "Evra Product information". Health Canada. 2018-06-21. Retrieved 17 February 2020.
  8. ^ a b "Evra transdermal patch - Summary of Product Characteristics (SmPC)". (emc). 29 November 2018. Archived from the original on 7 November 2017. Retrieved 17 February 2020.
  9. ^ a b "Evra EPAR". European Medicines Agency. 17 September 2018. Retrieved 18 February 2020.